it's the entire point of listing though isn't it... to raise capital...
Printable View
it's the entire point of listing though isn't it... to raise capital...
(although GFI and RUA arent exactly tough competition!)
Hahahaha so true GFI is a joke
You're quite right these guys if anything are very much masters at being a public company, they have competed 5 capital raises, made an acquisition and done a merger. If anything they do it better than anyone else, they might even consider becoming an investment bank while they're at it. While its the point of being a listed company, its not the point of raising capital. They are meant to raise capital to create shareholder value and so far they have not created any shareholder value on todays share price. They have just raised capital less than 3 months ago and they are already thinking about their next capital raise, which is what makes the announced dual listing comical.
19/6/2019 - Raised $10m at 50 cents at IPO
Total shares after issue 102,000,000 at 50 cents that’s a $51m company
4/5/2020 – Raised $6m at 38 cents
Total shares after issue 121,321,301 at 38 cents that a $46m company
3/8/2021 – Raised $4.5m at 40 cents
Total shares after issue 135,280,551 at 40 cents that’s $54m company
8/9/2022 – Raised $3.2m at 30 cents
Total shares after issue 147,891,069 at 30 cents that’s a $44m company
30/5/2023 – Raised $7m at 29 cents
Total shares after issue (includes raise and merger) 320,533,594 at 29 cents that’s a $93m company
Todays share price 21.5 cents with 320,533,594 shares on issue with a valuation of $69m
Having raised $30.7m to date
https://www.nzx.com/announcements/417311
Revenue up 5,408%!! :cool:
I would have thunk this would have been on the radar before/when they did the merger? Especially when they aren't so flush with cash and while their "expotential growth in demand" kicks in and translates to sales......:sleep:
https://www.nzx.com/announcements/419292
Cannasouth Ltd (NZX: CBD) announced today that following the merger with Eqalis, effective 1 June 2023, opportunities for cost rationalisation through operational efficiencies and greater focus were identified. A range of initiatives are underway to deliver the efficiency gains and to reduce cash spend by around $400,000 per month once restructuring is fully implemented. The restructure will retain key business intellectual property and functionality to meet immediate revenue goals.
https://www.nzx.com/announcements/421556
Paraphrased to "Please send money....."
https://www.youtube.com/watch?v=6x9crIZFKRU
0:52 We were commissioned by Cannasouth NZX CBD to write some research.
1:20 That chart there is the new cannabis Ventures Global cannabis stock index so new cannabis ventures has been tracking the cannabis sector for the world for the best part of two decades and they've constructed this index from various publicly traded cannabis companies.
1:42 Cannabis is a boom or bust industry when it booms it booms hard, when it busts it busts hard. There've been four booms over the last decade. The biggest was 2013 when Canada formalized the regulatory environment for medicinal cannabis and Canadian stocks led the charge in terms of creating this new industry globally.
There have been subsequent booms in 2016, 2020 during covid and I'm predicting that cannabis 4.0 is coming up but it's going to have to overcome the bear market that's been in since about 2021.
2:47 My thinking is that cannabis is base building at the moment, 24 it's got a decent chance of being in a good year.
2:59 Winners are coming through in terms of profitable and rapidly growing companies benefiting from a rising user base . We're seeing that around the world, US Canada and now we are starting to see it here in Australia.
3:14 TRK a company that we know quite well. And they started from zero and now are up to $90 million in revenues.
4:08 So is Cannasouth over in New Zealand. Companies are working on GMP, good manufacturing practice where they make their cannabis products like you would make regular pharmaceuticals They're going to be one of the winners here. The other winners are companies with clinical data. It no longer cuts it just to say that cannabis would makes a great painkiller what you want to know is that cannabis might act against sleep disorders for example or Autism Spectrum disorders or Parkinson's, or you name the disease condition. Cannabis is a pretty useful molecule.
6:41 This is the chart of Cannasouth on NZX. Hasn't been a great couple of years for Cannasouth. Middle of 2023 they completed a merger with a competitor called Eales so this is now a fully integrated cannabis company based in New Zealand probably the dominant player in that market with a growing suite of products, new generation products coming through, links up to the various distribution channels in in New Zealand, ready to start selling in Australia and globally. The chart looks terrible it's fair to say.
Business at this company has never been better
7:44 Cannasouth, the company's actually given some revenue guidance about how much they expect to make in 2024, they're talking six to 10 million. To give guidance is always a good catalyst.
8:09 So keep an eye on that index we were talking about there. If that starts to move then
Cannasouth can move with it. So let's talk about why investors should put this one on their radar screen. It's got a decent size, it's 57 million market cap on NZX alone, it's contemplating a dual listing on ASX for next year. The important thing is itÂ’s fully integrated. They actually grow the product in a number of cultivation facilities in New Zealand and then process it at a plant they've got at Hamilton on the North Island.
8:42 Strong NZX regulations were put in place by the Ardern government governing how you can act as a medicinal cannabis company in New Zealand and how products can get approved. The New Zealand Market has traditionally been an import market.
9:05 I've been astounded by the number of new patients coming on the market in terms of being able to access cannabis medicines in Australia. This is not the case in New Zealand, but in Australia in the state of Queensland any general practitioner can prescribe a cannabis medicine whether not or not it's an approved product.
9:34 Into 2024 this company's raising some money at the moment hence the briefing we just did over in New Zealand. Our research is good background to that we encourage you to go check it out.
Pitt Street research.com is the place to find that.
More 'trouble at mill'.......
https://www.nzx.com/announcements/424059
Cannasouth Limited (NZX: CBD, Cannasouth) announces that Mrs. Hilary Webber, Independent Non-executive Director, and Mr. Greg Misson, Executive Director, of Cannasouth will step down from their positions with the company effective 1 January and 5 January 2024 respectively. Mr. Misson will continue in his executive management role to 31 March 2024.
Big trouble in CBD world.....
"CBD has sought the trading halt as it is in dispute with some of its secured convertible note holders, which has the potential to prejudice an urgent additional capital raise CBD is seeking to finalise and announce to market. CBD has an urgent need to secure funding to remain solvent."
This won't help in shareholders confidence when supporting a capital raise. Could be massive issues if they can't get the cash coming in to grow this thing to profitability.
Not Holding
Code for, if the convertible notes are not converted from debt to equity then we cannot trade as we are insolvent.
Anyone on this forum pumped money this high risk venture?
Wasn't this one all moonbeams about how the magic stuff just mysteriously took itself off to market
and was a little ripper in progress - so much so that all the boys & girls for as far as the
eye could see were clambering over one another to fill their pockets with CBD stonks ? ;)
What went so badly wrong in just 18 months ? ;) Did the sun stop shining ?